Recurrent hydatidiform mole: a case report highlighting NLRP7 gene mutations and genetic imprinting
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20262563Keywords:
Recurrent hydatidiform mole, NLRP7 gene mutation, Gestational trophoblastic disease, Genomic imprinting, Biparental moleAbstract
Recurrent hydatidiform mole (RHM) is a rare form of gestational trophoblastic disease and is frequently associated with mutations in maternal-effect genes, particularly NLRP7, which play a critical role in early embryonic development and genomic imprinting. We report the case of a 26-year-old woman (G7P0) who presented at 9 weeks’ gestation with features suggestive of a complete molar pregnancy. Ultrasonography demonstrated a heteroechoic intrauterine mass, and serum β-human chorionic gonadotropin levels were markedly elevated at 272,600 IU/l. Her obstetric history was significant for 6 prior molar pregnancies, highlighting the recurrent nature of the condition; one of these pregnancies progressed to low-risk gestational trophoblastic neoplasia with pulmonary metastases, which was successfully managed with multiagent chemotherapy and close follow-up. In view of the recurrent disease, genetic evaluation was undertaken and revealed compound heterozygous pathogenic variants in the NLRP7 gene, including an exon 3 deletion and an exon 4 truncation. The patient received comprehensive counseling regarding the genetic etiology of her condition, its oncologic implications, and future reproductive options. Biallelic NLRP7 mutations result in abnormal oocyte development and impaired genomic imprinting, leading to recurrent molar gestations and a significantly reduced likelihood of achieving a viable pregnancy with autologous oocytes. Ovum donation remains the most viable reproductive option for affected women. This case underscores the importance of early genetic evaluation in women with recurrent molar pregnancies to guide individualized management, surveillance, and reproductive counseling.
References
Berkowitz RS, Goldstein DP. Molar pregnancy. N Engl J Med. 2009;360(16):1639-45.
Sebire NJ, Fisher RA, Foskett M, Rees H, Seckl MJ, Newlands ES. Risk of recurrent hydatidiform mole and subsequent pregnancy outcome. BJOG. 2003;110(1):22-6.
Savage P, Williams J, Wong SL, Short D, Casalboni S, Catalano K, et al. Demographics of molar pregnancy. J Reprod Med. 2010;55(7-8):341-5.
Sebire NJ, Seckl MJ. Gestational trophoblastic disease. BMJ. 2008;337:a1193.
Murdoch S, Djuric U, Mazhar B, Seoud M, Khan R, Kuick R, et al. Mutations in NALP7 cause recurrent hydatidiform moles. Nat Genet. 2006;38(3):300-2.
Nguyen NM, Slim R. Genetics and epigenetics of recurrent hydatidiform moles. Clin Genet. 2014;85(4):301-8.
Mahadevan S, Sathappan V, Utama B, Lorenzo I, Kaskar K, Van den Veyver IB, et al. NLRP7 regulates trophoblast lineage differentiation. Hum Mol Genet. 2014;23(3):706-20.
Lurain JR. Gestational trophoblastic disease: epidemiology and diagnosis. Am J Obstet Gynecol. 2010;203(6):531-9.
Ngan HY, Seckl MJ, Berkowitz RS, Xiang Y, Golfier F, Sekharan PK, et al. FIGO update on GTD management. Int J Gynaecol Obstet. 2015;131(2):S123-6.
Seckl MJ, Sebire NJ, Berkowitz RS. Gestational trophoblastic disease. Lancet. 2010;376(9742):717-29.
Slim R, Wallace EP. NLRP7 mutations and role of oocyte donation. Reprod Biomed Online. 2013;26(4):373-9.
Parry DA, Logan CV, Hayward BE, Shires M, Landolsi H, Diggle C, et al. Mutations causing familial biparental hydatidiform mole implicate C6orf221 (KHDC3L). Nat Genet. 2011;43(12):1211-4.
Nguyen NM, Ge ZJ, Reddy R, Fahiminiya S, Sauthier P, Bagga R, et al. Mutations in KHDC3L cause recurrent hydatidiform moles. Hum Mol Genet. 2014;23(4):992-1000.